-
company launched a
collaboration MacroGenics and
their preclinical cancer treatment, MGD015. The deal
could net
MacroGenics more than $740 million. In September...
-
partnership with
Ortho Pharmaceuticals, and was then
further developed at
MacroGenics, Inc.,
including a
collaboration with Eli
Lilly to
conduct the first...
-
September 2014,
Takeda announced it
would expand a
collaboration with
MacroGenics,
valued up to US$1.6 billion. The
collaboration focused on the co-development...
-
Business Wire. "
MacroGenics Earns $15
Million Milestone Following U.S. FDA
Approval of
Zynyz (retifanlimab-dlwr)" (Press release).
MacroGenics. 22
March 2023...
-
member of the B7
family of
immune regulators. This drug was
developed by
MacroGenics, Inc.
Statement On A
Nonproprietary Name
Adopted By The USAN Council...
- drug was
created by
Raven biotechnologies,
which was
later acquired by
MacroGenics. It was
engineered to
increase affinity for CD16A
polymorphisms and decrease...
- is now
regarded as co-inhibitory. The
American biotechnology company MacroGenics is
working on MGA271 is an Fc-optimized
monoclonal antibody that targets...
- bloomberg.com.
Retrieved April 19, 2018. "
MacroGenics Completes Series B
Financing |
MacroGenics, Inc".
MacroGenics, Inc.
Retrieved April 16, 2018. "Mr. Guy...
- (MGA012) is a
humanized IgG4
monoclonal antibody developed by
Incyte and
MacroGenics. AMP-224 by AstraZeneca/MedImmune and
GlaxoSmithKline AMP-514 (MEDI0680)...
- including:
Cytopeia (acquired by BD in 2008),
Integrated Diagnostics,
Macrogenics,
NanoString Technologies, and
Accelerator Corporation.
Accelerator Corporation...
